(Q39632681)

13 September 2017

title

Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors (English)

1 reference

13 September 2017

1 reference

Deborah T Blumenthal

1

1 reference

13 September 2017

Michal Yalon

2

1 reference

13 September 2017

Gilad W Vainer

3

1 reference

13 September 2017

Alexander Lossos

4

1 reference

13 September 2017

Shlomit Yust

5

1 reference

13 September 2017

Lior Tzach

6

1 reference

13 September 2017

Emanuela Cagnano

7

1 reference

13 September 2017

Dror Limon

8

1 reference

13 September 2017

Felix Bokstein

9

1 reference

13 September 2017

language of work or name

1 reference

4 July 2016

1 reference

Journal of Neuro-Oncology

13 September 2017

published in

1 reference

13 September 2017

volume

129

1 reference

13 September 2017

issue

3

1 reference

13 September 2017

page(s)

453-460

1 reference

https://scigraph.springernature.com/pub.10.1007/s11060-016-2190-1

13 September 2017

exact match

0 references

cites work

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2190-1

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2190-1

Stereotactic radiosurgery (SRS) in high-grade glioma: judicious selection of small target volumes improves results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2190-1

Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2190-1

Feasibility, safety, and indications for surgical biopsy of intrinsic brainstem tumors in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2190-1

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2190-1

The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2190-1

PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2190-1

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2190-1

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2190-1

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2190-1

Pembrolizumab versus Ipilimumab in Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2190-1

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2190-1

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2190-1

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2190-1

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2190-1

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2190-1

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2190-1

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2190-1

Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2190-1

Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2190-1

PD-1 blockade induces responses by inhibiting adaptive immune resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2190-1

PD-L1 expression and prognostic impact in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2190-1

Signatures of mutational processes in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2190-1

High frequency of mismatch repair deficiency among pediatric high grade gliomas in Jordan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2190-1

Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2190-1

Neoantigens in cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2190-1

Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2190-1

Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2190-1

Radiotherapy complements immune checkpoint blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2190-1

Successful treatment with an anti-PD-1 antibody for progressing brain metastases in renal cell cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2190-1

Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2190-1

Principles of conservative prescribing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2190-1

Going "social" to access experimental and potentially life-saving treatment: an assessment of the policy and online patient advocacy environment for expanded access

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2190-1

A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27377654

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27377654

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11060-016-2190-1

1 reference

13 September 2017

1 reference